Ultra-low-molecular-weight heparins: Precise structural features impacting specific anticoagulant activities

Summary

Ultra-low-molecular-weight heparins (ULMWHs) with better efficacy and safety ratios are under development; however, there are few structural data available. The main structural features and molecular weight of ULMWHs were studied and compared to enoxaparin. Their monosaccharide composition and average molecular weights were determined and preparations studied by nuclear magnetic resonance spectroscopy, scanning ultraviolet spectroscopy, circular dichroism and gel permeation chromatography. In general, ULMWHs presented higher 3-O-sulphated glucosamine and unsaturated uronic acid residues, the latter being comparable with their higher degree of depolymerisation. The analysis showed that ULMWHs are structurally related to LMWHs; however, their monosaccharide/oligosaccharide compositions and average molecular weights differed considerably explaining their different anticoagulant activities. The results relate structural features to activity, assisting the development of new and improved therapeutic agents, based on depolymerised heparin, for the prophylaxis and treatment of thrombotic disorders.

Keywords

Heparin - enoxaparin - molecular weight - spectroscopy - anticoagulant activity

• References

• 1 Nader HB, McDuffie NM, Dietrich CP. Heparin fractionation by electrofocusing: presence of 21 components of different molecular weights. Biochem Biophys Res Commun 1974; 57: 488-493.
• 2 McDuffie NM, Dietrich CP, Nader HB. Electrofocusing of heparin: fractionation of heparin into 21 components distinguishable from other acidic mucopolysaccharides. Biopolymers 1975; 14: 1473-1486.
• 3 Dietrich CP, Nader HB, Perlin AS. The heterogeneity of heparan sulfate from beef-lung tissue: p.m.r.-spectral evidence. Carbohydr Res 1975; 41: 334-338.
• 4 Bianchini P, Osima B, Parma B. et al. Structural studies and "in vivo" and "in vitro" pharmacological activities of heparin fractions and fragments prepared by chemical and enzymic depolimerization. Thromb Res 1985; 40: 49-58.
• 5 Kearon C, Kahn SR, Agnelli G. et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133 (06) 454S-545S.
• 6 Jin L, Abrahams JP, Skinner R. et al. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 1997; 94: 14683-14688.
• 7 Viskov C, Just M, Laux V. et al. Description of the chemical and pharmacological characteristics of a new hemisynthetic ultra-low-molecular-weight heparin, AVE5026. J Thromb Haemost 2009; 7: 1143-1151.
• 8 Guerrini M, Guglieri S, Naggi A. et al. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2007; 33: 478-487.
• 9 Vismara E, Pierini M, Mascellani G. et al. Low-molecular-weight heparin from Cu2+ and Fe2+ Fenton type depolymerisation processes. Thromb Haemost 2010; 103: 613-622.
• 10 Ahsan A, Jeske W, Hoppensteadt D. et al. Molecular profiling and weight determination of heparins and depolymerized heparins. J Pharm Sci 1995; 84: 724-727.
• 11 Clevidence BA, Failla ML, Vercellotti JR. et al. Pharmacokinetics of catalytically tritiated glycosaminoglycans in the rat. Arzneimittelforschung 1983; 33: 228-230.
• 12 Viccini G, Martinelli TR, Cognialli RC. et al. Exopolysaccharide from surface-liquid culture of Clonostachys rosea originates from autolysis of the biomass. Arch Microbiol 2009; 191: 369-378.
• 13 Bednarek E, Sitkowski J, Bocian W. et al. An assessment of polydispersed species in unfractionated and low molecular weight heparins by diffusion ordered nuclear magnetic resonance spectroscopy method. J Pharm Biomed Anal 2010; 53: 302-308.
• 14 Biberovic V, Grondard L, Mourier P. et al., inventors; Aventis Pharma S.A., assignee. Mixtures of sulfated oligosaccharides. USA.. 2011
• 15 Guerrini M, Naggi A, Guglieri S. et al. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem 2005; 337: 35-47.
• 16 Lima MA, de Farias EHC, Rudd TR. et al. Low molecular weight heparins: Structural differentiation by spectroscopic and multivariate approaches. Carbohyd Polym 2011; 85: 903-909.
• 17 Mascellani G, Guerrini M, Torri G. et al. Characterization of di- and monosulfated, unsaturated heparin disaccharides with terminal N-sulfated 1,6-anhydro-beta-D-glucosamine or N-sulfated 1,6-anhydro-beta-D-mannosamine residues. Carbohydr Res 2007; 342: 835-842.
• 18 Enoxaparin Sodium Monograph. Pharmacopeial Forum 2009; 35: 2041-2042.
• 19 Hirsh J, Warkentin TE, Raschke R. et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1998; 114 (05) 489S-510S.
• 20 Guerrini M, Guglieri S, Casu B. et al. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue. J Biol Chem 2008; 283: 26662-26675.
• 21 Martinez-Gonzalez J, Vila L, Rodriguez C. Bemiparin: second-generation, low-molecular-weight heparin for treatment and prophylaxis of venous thromboembolism. Expert Rev Cardiovasc Ther 2008; 6: 793-802.